Groups | Cases | Low | High | Positive rate (%) | P-value | High expression rate (%) | P-value | ||
---|---|---|---|---|---|---|---|---|---|
(−) | (+) | (++) | (+++) | ||||||
FIGO stage | |||||||||
 I-II | 38 | 8 | 11 | 12 | 7 | 78.9% | P = 0.209 | 50.0% | P = 0.101 |
 III-IV | 60 | 7 | 13 | 16 | 24 | 85.5% | 66.7% | ||
Differentiation | |||||||||
 Well- Moderate | 49 | 9 | 14 | 14 | 12 | 81.6% | P = 0.4 | 53.1% | P = 0.149 |
 Poor | 49 | 6 | 10 | 14 | 19 | 87.8% | 67.3% | ||
Lymphatic metastasis | |||||||||
 No | 62 | 8 | 16 | 22 | 16 | 87.1% | P = 0.582 | 61.3% | P = 0.808 |
 Yes | 29 | 5 | 7 | 5 | 12 | 82.8% | 58.6% | ||
 Unknowna | 7 | 2 | 1 | 1 | 3 | 71.4% | 57.1% | ||
Pathological type | |||||||||
 Serous | 45 | 6 | 11 | 13 | 15 | 86.7% | P = 0.158 | 62.2% | P = 0.440 |
 Mucinous | 9 | 3 | 1 | 2 | 3 | 66.7% | 55.6% | ||
 Endometrioid | 15 | 3 | 4 | 4 | 4 | 80% | 53.3% | ||
 Clear cell carcinoma | 7 | 2 | 3 | 1 | 1 | 71.4% | 28.6% | ||
 Poorly differentiated adenocarcinoma | 22 | 1 | 6 | 5 | 10 | 95.5% | 68.2% |